These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 24890762)

  • 1. A case of tumour necrosis factor-α inhibitor- and rituximab-induced plantar pustular psoriasis that completely resolved with tocilizumab.
    Jayasekera P; Parslew R; Al-Sharqi A
    Br J Dermatol; 2014 Dec; 171(6):1546-9. PubMed ID: 24890762
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Palmoplantar subcorneal pustular dermatosis following adalimumab therapy for rheumatoid arthritis.
    Sauder MB; Glassman SJ
    Int J Dermatol; 2013 May; 52(5):624-8. PubMed ID: 23489057
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plantar pustulosis during rituximab therapy for rheumatoid arthritis.
    Brunasso AM; Massone C
    J Am Acad Dermatol; 2012 Oct; 67(4):e148-50. PubMed ID: 22980273
    [No Abstract]   [Full Text] [Related]  

  • 4. [Development of psoriasis in a patient with reumatoid arthritis after rituximab].
    Feced Olmos CM; Ivorra Cortés J; Alegre Sancho JJ; Roman Ivorra JA
    Med Clin (Barc); 2014 Jan; 142(1):40-1. PubMed ID: 23510613
    [No Abstract]   [Full Text] [Related]  

  • 5. Tocilizumab-induced psoriasiform rash in rheumatoid arthritis.
    Palmou-Fontana N; Sánchez Gaviño JA; McGonagle D; García-Martinez E; Iñiguez de Onzoño Martín L
    Dermatology; 2014; 228(4):311-3. PubMed ID: 24942661
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Ustekinumab in a patient with Crohn's disease and anti-TNF-α-induced psoriasis].
    Sansó Sureda A; Rocamora Durán V; Sapiña Camaró A; Royo Escosa V; Bosque López MJ
    Gastroenterol Hepatol; 2011 Oct; 34(8):546-50. PubMed ID: 21665330
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Psoriasis associated with anti-tumour necrosis factor therapy in inflammatory bowel disease: a new series and a review of 120 cases from the literature.
    Cullen G; Kroshinsky D; Cheifetz AS; Korzenik JR
    Aliment Pharmacol Ther; 2011 Dec; 34(11-12):1318-27. PubMed ID: 21957906
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ustekinumab treatment of TNF antagonist-induced paradoxical psoriasis flare in a patient with psoriatic arthritis: case report and review.
    Puig L; Morales-Múnera CE; López-Ferrer A; Geli C
    Dermatology; 2012; 225(1):14-7. PubMed ID: 22890275
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Successful effect of tocilizumab in anti-TNF-α-induced palmoplantar pustulosis in rheumatoid arthritis.
    Rueda-Gotor J; González-Gay MA; Blanco Alonso R; Gonzalez-Vela C; Lopez-Obregon C; González-López MA
    Joint Bone Spine; 2012 Oct; 79(5):510-3. PubMed ID: 22857979
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Successful treatment of severe psoriasis and psoriatic arthritis with adalimumab.
    Chew AL; Bennett A; Smith CH; Barker J; Kirkham B
    Br J Dermatol; 2004 Aug; 151(2):492-6. PubMed ID: 15327561
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Flare of pustular psoriasis after initiating ustekinumab therapy.
    Wenk KS; Claros JM; Ehrlich A
    J Dermatolog Treat; 2012 Jun; 23(3):212-4. PubMed ID: 21254881
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TNF-α inhibitor (adalimumab) induced psoriasis: a case report.
    Al-Mutairi A; Elkashlan M; Al-Fayed HM; Swayed M
    Australas J Dermatol; 2012 May; 53(2):157. PubMed ID: 22571571
    [No Abstract]   [Full Text] [Related]  

  • 13. Tumor necrosis factor-associated palmoplantar pustular psoriasis treated with interleukin 6 blocker.
    Younis S; Rimar D; Slobodin G; Rosner I
    J Rheumatol; 2012 Oct; 39(10):2055-6. PubMed ID: 23028035
    [No Abstract]   [Full Text] [Related]  

  • 14. Successful treatment of adalimumab-induced paradoxical psoriatic arthritis with risankizumab.
    Watabe D; Amano H
    Eur J Dermatol; 2020 Oct; 30(5):611-612. PubMed ID: 33185535
    [No Abstract]   [Full Text] [Related]  

  • 15. Association between the type and length of tumor necrosis factor inhibitor therapy and myocardial infarction risk in patients with psoriasis.
    Wu JJ; Poon KY; Bebchuk JD
    J Drugs Dermatol; 2013 Aug; 12(8):899-903. PubMed ID: 23986163
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Survival rate of antitumour necrosis factor-α treatments for psoriasis in routine dermatological practice: a multicentre observational study.
    Esposito M; Gisondi P; Cassano N; Ferrucci G; Del Giglio M; Loconsole F; Giunta A; Vena GA; Chimenti S; Girolomoni G
    Br J Dermatol; 2013 Sep; 169(3):666-72. PubMed ID: 23647206
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Paradoxical cutaneous reactions associated with tocilizumab therapy].
    Sparsa L; Afif N; Bularca S; Fricker A; Thiebault S; Dahan E; Wendling D; Sibilia J; Ardizzone M
    Rev Med Interne; 2014 Sep; 35(9):613-6. PubMed ID: 24630585
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Induction and exacerbation of psoriasis with TNF-blockade therapy: a review and analysis of 127 cases.
    Ko JM; Gottlieb AB; Kerbleski JF
    J Dermatolog Treat; 2009; 20(2):100-8. PubMed ID: 18923992
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cutaneous side-effects in patients with rheumatic diseases during application of tumour necrosis factor-alpha antagonists.
    Lee HH; Song IH; Friedrich M; Gauliard A; Detert J; Röwert J; Audring H; Kary S; Burmester GR; Sterry W; Worm M
    Br J Dermatol; 2007 Mar; 156(3):486-91. PubMed ID: 17300238
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cytokine imbalance with increased production of interferon-alpha in psoriasiform eruptions associated with antitumour necrosis factor-alpha treatments.
    Seneschal J; Milpied B; Vergier B; Lepreux S; Schaeverbeke T; Taïeb A
    Br J Dermatol; 2009 Nov; 161(5):1081-8. PubMed ID: 19681863
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.